Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Combined With Trasotuzumab and Pertuzumab in Neoadjuvant Treatment for Elderly Patients With HER-2 Positive Breast Cancer
NCT07695259Phase 4Recruiting
- Sponsor
- Wen-Ming Cao
- Start
- May 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 4 trial of olaparib in breast cancer, sponsored by Wen-Ming Cao. Started May 2026; status: recruiting.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07695259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07695259.